文献速递呼吸道感染

接受利妥昔单抗治疗患者肺孢子菌肺炎的一级预防

Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
PubMed 文献 · Chest · 2021-11-14

该回顾性研究纳入2002至2018年韩国一家三级转诊中心3524例首次暴露于利妥昔单抗的患者,比较预防性使用TMP-SMX组与对照组的1年PJP发病率。预防组PJP发生率显著低于对照组(校正亚分布风险比0.20,95%CI 0.10-0.42),TMP-SMX相关不良反应多为轻至中度。

要点

  • 利妥昔单抗治疗患者预防性使用TMP-SMX可显著降低1年PJP发病率。
  • TMP-SMX相关不良反应发生率为18.1/100人年,多为轻至中度。
  • 预防1例PJP需治疗32例,而发生1例严重不良反应需治疗101例。

核心结论

  • 在接受利妥昔单抗治疗的患者中,TMP-SMX预防可显著降低PJP发病率,且安全性可耐受。

研究设计与样本

  • 回顾性研究纳入2002至2018年韩国一家三级转诊中心3524例首次暴露于利妥昔单抗的患者(血液病2500例,风湿病559例,实体器官移植前/后465例)。
  • 按利妥昔单抗开始后28天内是否预防性使用TMP-SMX分为对照组(n=2523)和预防组(n=1001),并进行意向性分析和时变分析。
  • 主要结局为TMP-SMX对1年PJP发病率的预防效果,应用逆概率治疗加权以最小化基线失衡;次要结局包括TMP-SMX相关不良反应发生率。

主要发现

  • 中位随访2,759.9人年期间共发生92例PJP感染,死亡率为27.2%。
  • 预防组PJP发病率显著低于对照组(校正亚分布风险比0.20,95%CI 0.10-0.42)。
  • 时变分析中,TMP-SMX给药期间仅发生1例PJP感染(校正亚分布风险比0.01,95%CI 0.003-0.16)。
  • TMP-SMX相关不良反应发生率为18.1(95%CI 14.6-22.2)/100人年,大多为轻至中度。

关键数值与推荐

  • 基于10例严重不良反应,伤害所需人数(NNH)为101(95%CI 61.9-261.1)。
  • 预防1例PJP感染所需治疗人数(NNT)为32(95%CI 24.8-39.4)。

临床怎么用

  • 对于接受利妥昔单抗治疗的患者,可考虑预防性使用TMP-SMX以降低PJP风险。
  • 决策时需权衡PJP预防获益与TMP-SMX相关不良反应风险,尤其关注严重不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although previous studies suggested that rituximab increases the risk of Pneumocystis jirovecii pneumonia (PJP), it is uncertain whether its primary prophylaxis for PJP is justified. RESEARCH QUESTION: Does the benefit of primary prophylaxis for PJP in patients receiving rituximab treatment outweigh the potential risk of the prophylaxis? STUDY DESIGN AND METHODS: This retrospective study included 3,524 patients (hematologic diseases, 2,500; rheumatic diseases, 559; pre/post-solid organ transplantation, 465) first exposed to rituximab between 2002 and 2018 in a tertiary referral center in South Korea. Patients were classified into a control group (n = 2,523) and a prophylaxis group (n = 1,001) according to the administration of prophylactic trimethoprim-sulfamethoxazole (TMP-SMX) during the first 28 days after the start of rituximab (intention-to-treat analysis). In addition, exposure to TMP-SMX was examined as a time-varying variable (time-varying analysis). The primary outcome was the prophylactic effect of TMP-SMX on the 1-year incidence of PJP. Inverse probability of treatment weights was applied to minimize the baseline imbalance. The secondary outcome included the incidence of adverse drug reactions (ADRs) related to TMP-SMX. RESULTS: Over 2,759.9 person-years, 92 PJP infections occurred, with a mortality rate of 27.2%. The prophylaxis group showed a significantly lower incidence of PJP (adjusted subdistribution hazard ratio, 0.20 [95% CI, 0.10-0.42]) than the control group. This result was consistent with the results of time-varying analysis, in which only one PJP infection occurred during TMP-SMX administration (adjusted subdistribution hazard ratio, 0.01 [0.003-0.16]). The incidence of ADRs related to TMP-SMX was 18.1 (14.6-22.2)/100 person-years, and most were of mild to moderate severity. On the basis of 10 severe ADRs, the number needed to harm was 101 (61.9-261.1), whereas the number needed to prevent one PJP infection was 32 (24.8-39.4). INTERPRETATION: TMP-SMX prophylaxis significantly reduces PJP incidence with a tolerable safety profile in patients receiving rituximab treatment.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Park JW, Curtis JR, Jun KI, et al. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab. Chest. 2021. PMID: 34788668. doi:10.1016/j.chest.2021.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。